# ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

> **NCT00208312** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 787 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Regadenoson
- **DRUG:** Adenosine

## Key facts

- **NCT ID:** NCT00208312
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 787 (ACTUAL)
- **Last updated:** 2009-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00208312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00208312, "ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00208312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*